I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Infectious Disease APASL 2025
Roche and Genentech at

APASL 2025

March 26 - March 30
Beijing, China
apasl.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Mar 29 / Roche and Genentech
Efficacy and safety of xalnesiran in combination with the checkpoint inhibitor PD-L1 LNA in virologically suppressed participants with chronic hepatitis B: results from the Piranga phase 2, randomized, controlled, adaptive, open-label platform study
This presentation reports the primary and selected secondary and exploratory endpoint results from the Piranga (NCT04225715) phase 2 platform study. The combination of xalnesiran (RO7445482), a GalNAc-conjugated small interfering ribonucleic acid (siRNA) targeting HBsAg transcripts, with the checkpoint inhibitor PD-L1 LNA (RO7191863), a GalNAc-conjugated locked nucleic acid inhibiting the expression of the programmed death-ligand 1, either concurrently or sequentially, achieved limited efficacy on HBsAg loss and its durability. Xalnesiran with PD-L1 LNA was generally safe and well-tolerated.
Infectious Disease Hepatitis B virus infection APASL-2025

Sign up or login to unlock the full suite of MEDICALLY features
Mar 29 / Roche and Genentech
Similarities and differences of xalnesiran-based combination regimens aimed to achieve functional cure in the Piranga phase 2 platform study
This exploratory post-hoc analysis reports on similarities and differences between the different xalnesiran-based combinations evaluated in the Piranga phase 2 platform trial, shedding light on findings that may explain the observed primary results. The combination of xalnesiran with peginterferon α achieved high rates of HBsAg loss through an increase in depth of HBsAg reduction, specifically in pts with low baseline HBsAg. Moreover, the absence of association between on-treatment ALT elevation and the HBsAg reduction or loss indicates that ALT flares may not be required to achieve HBsAg loss with xalnesiran-based combination regimen.
Infectious Disease Hepatitis B virus infection APASL-2025

Sign up or login to unlock the full suite of MEDICALLY features
Mar 28 / Roche
Evaluation of blood droplet volumes on the Cobas Plasma Separation Card for HCV RNA testing in resource-limited settings
Detection of viral RNA is essential for diagnosis of hepatitis C virus (HCV). Collection and preservation of plasma, the preferred specimen type for HCV RNA testing, can present challenges in remote and resource-limited areas. The Cobas Plasma Separation Card (PSC) is a matrix for preparing dried plasma spots for PCR analysis with no cold chain requirements, facilitating sample collection in remote, underserved areas. The PSC is designed to use capillary blood (140 µL) collected through a fingerstick and capillary tube collection. This study explored qualitative and quantitative HCV RNA detection with the PSC spotted with different venous blood volumes, compared with results from plasma samples.
Infectious Disease Hepatitis C virus infection APASL-2025
09:00 AM
Duration 24hrs Beijing, China
A novel mechanistic viral dynamics modeling (MVDM) framework to characterize the effect of combination therapies in chronic hepatitis B and evaluate the influence of individual characteristics in the Piranga phase 2 platform study
Claire McGeown
Infectious Disease | Hepatitis B virus infection

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
07:30 AM
Duration 10mins Beijing, China
Evaluation of blood droplet volumes on the Cobas Plasma Separation Card for HCV RNA testing in resource-limited settings
Aline Kessler
Infectious Disease | Hepatitis C virus infection

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:10 AM
Duration 10mins Beijing, China
Efficacy and safety of xalnesiran in combination with the checkpoint inhibitor PD-L1 LNA in virologically suppressed participants with chronic hepatitis B: results from the Piranga phase 2, randomized, controlled, adaptive, open-label platform study
Man-Fung Yuen
Infectious Disease | Hepatitis B virus infection

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
01:20 AM
Duration 10mins Beijing, China
Similarities and differences of xalnesiran-based combination regimens aimed to achieve functional cure in the Piranga phase 2 platform study
Rémi Kazma
Infectious Disease | Hepatitis B virus infection

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.